Chemours Co
NYSE:CC
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
16.79
32.47
|
| Price Target |
|
We'll email you a reminder when the closing price reaches USD.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
Chemours Co
You don't have any saved screeners yet
Good morning. My name is Rob and I will be your conference operator today. At this time I would like to welcome everyone to The Chemours Company Fourth Quarter 2021 Earnings Call. All lines have been placed on mute to prevent any background noise. After the speakers’ remarks, there will be a question-and-answer session. [Operator Instructions] Thank you. Jonathan Lock, Senior Vice President and Chief Development Officer, you may begin your conference.
Good morning and welcome to the Chemours Company's Fourth Quarter and Full-Year 2021 Earnings Conference Call. I'm joined today by Mark Newman, President and Chief Executive Officer and Sameer Ralhan, Senior Vice President and Chief Financial Officer. Before we start, I'd like to remind you that comments made on this call, as well as the supplemental information provided in our presentation and on our website, contain forward-looking statements that involve risks and uncertainties, including the impact of COVID-19 on our business and operation. And the other risks and uncertainties described in the documents, Chemours has filed with the SEC.
These forward-looking statements are not guarantees of future performance, and are based on certain assumptions and expectations of future events that may not be realized. Actual results may differ and Chemours undertakes no up-duty to update any forward-looking statements as a result of future developments or new information. During the course of this call, management will refer to certain non-GAAP financial measures, that we believe are useful to investors evaluating the company's performance. A reconciliation of non-GAAP terms and adjustments are included in our release and at the end of this presentation. With that, I'll turn the call over to our CEO, Mark Newman, who will cover the highlights from the past quarter and full year. Mark?
Thank you, Jonathan. And thank you for joining us this morning. I will begin my remarks on Chart 3. 2021 was a year where the Chemours team pull together to deliver strong results quarter-after-quarter. Despite being a year full of challenges, our performance reflects strong customer demand for our products and our commitment to customer service and supply chain reliability through the toughest conditions, all underpinned by our company-wide commitment to the holistic safety and health of our workforce.
Revenue was up 28% year-over-year to $6.3 billion, adjusted EBITDA rose 49% to $1.3 billion. And we generated $543 million of free cash flow, consistent with our focus on sustainable growth and high-quality earnings across our businesses, with strong free cash flow conversion. 2021 was truly a team effort across the entire business. In our TT segment, we built what we believe is the strongest book of contracted business ever with strategic customers who appreciate our value proposition and with whom we can grow over time. In TSS, we delivered strong sales and margin performance despite auto OEM headwinds and look forward to the growth we can achieve on the U.S. AIM Act. And in APM, we achieved record setting results on both the top and bottom line in a business which is being driven by several exciting secular growth trends.
Finally, in chemical solutions, we completed the sale of our mining solutions business, which will give us greater bandwidth to focus on our industry-leading TT, TSS, and APM businesses. I'm proud of the results we're reporting today, and proud of the entire Chemours team that delivered them. I would also like to thank our customers for their trust and confidence in Chemours. But 2021 wasn't just about the financial results. We made significant contributions to the planet, our people, and the communities in which we operate through progress on our corporate responsibility commitments.
Chemours believes that together with our employees, customers, suppliers, and communities, we will create a better world through the power of our chemistry. Our chemistry is essential to so much of our daily lives today, and is also key to a more sustainable infrastructure, clean energy, and advanced electronics. In fact, we are integral to the U.S. semiconductor industry supply chain. And we're making significant investments to manufacture this chemistry responsibly with the latest abatement technology. All part of our commitment to reduce emissions of floor organic compounds by 99% and greenhouse gas emissions by 60% by 2030.
Additionally, we continue to focus on our remediation commitments at our key sites, including the barrier wall project at our Fayetteville, North Carolina plant. Finally, with the DuPont Corteva Chemours MOU behind us, we are actively working to address, manage and resolve risk to the company related to legacy PFAS liabilities. A good example of this is the resolution of legacy natural resource damage claims in the past year with the state of Delaware. As we look forward to 2022, our guidance reflects our confidence in Chemours and our intent to drive consistent performance through the cycle while generating significant free cash flow. We continue to invest behind key secular growth drivers, especially in clean energy and advanced electronics.
And behind innovative and responsible chemistry, that enables the sustainable products of the future, from advanced coatings to low GWP thermal solutions to fuel cells, and beyond. All while strengthening our balance sheet and returning the majority of our free cash flow to shareholders. Turning to the next chart, I'd like to highlight more of the good work we're doing across Chemours through our corporate responsibility commitment programs. Last quarter we discussed our evolved portfolio pillar, and how the AIM Act will help drive Opteon low GWP refrigerant adoption across the U.S.
Today, I'd like to cover our inspired people pillar. The inspired people pillar has been one where we have consistently delivered outstanding progress through all three platforms, safety excellence, vibrant communities, and employee empowerment. In the fourth quarter, we launched a new program we called ChemFEST short for the Chemours Future of Engineering Science trades and Technology. ChemFEST helps bring STEM education to under-resourced middle schools in communities in which we operate. This year, with an initial investment of $4.3 million, we're bringing improved access to early STEM education to schools around our Wilmington headquarters, our new Johnsonville site, and are chambers worksite. This program is a natural feeder to our FASC program, which targets high school seniors pursuing stem education at the college level.
In total, Chemours has committed over $15 million to our inspired people initiatives, and investment which will pay back many times over in the lives we change and the impact we have on the communities in which we operate. I'm proud of this work which reflects our company's strong commitment to purpose and people. And we'd like to think Ravinia Scarborough our Chief Brand Officer and her entire team for leading the charge over the last several years. With that, I'll turn things over to Sameer to review the financial results for the fourth quarter. I'll be back to talk about our guidance before turning to Q&A. Sameer.
Thanks, Mark. And thanks everyone for joining us today. Before I begin my remarks, I would also like to recognize all our employees for their outstanding efforts over the course of 2021. Your energy and determination were instrumental in delivering the outstanding financial results, which Mark and I have privilege to report. Let me turn to Chart 5 to cover the full year results. Our 2021 full year results were driven by strong demand across all three of our primary businesses, with a significant rebound in demand from 2020. Full year net sales rose $1.4 billion to $6.3 billion, volume and pricing across the portfolio, backed by solid operational performance drove the strong results. GAAP EPS more than doubled to $3.60 per share in 2021 from $1.32 per share in 2020.
Adjusted EPS was $4 per share in 2021. Also more than doubled a $1.98 per share we earned in 2020. Our full-year 2021 adjusted EBITDA was $1.313 billion up $434 million or 49% from the prior year. This resulted in adjusted EBITDA margins of 21% for the full year, up 300 basis points from 2020. Free cash flow continues to be a strong point for the company. In 2021, we generated $543 million of free cash flow. This is despite the shift to networking capital consumption in 2021 based on improved customer demand and inventory levels.
Our performance on free cash flow reflects a power of the business to generate significant cash through any part of the economic cycle, and reflects our collective effort to improve the earnings quality of the business and spend. Turning to Chart 6 and our fourth quarter results. Fourth quarter net sales of $1.6 billion were up 18% from the fourth quarter, 2020. Price gains were strong across the breadth of the portfolio, while volume was up across most of our segments. Adjusted EBITDA rose 25% in the fourth quarter to $307 million, resulting in slight margin expansion to 19% versus 18% in last year's fourth quarter. Free cash flow was $131 million due to higher working capital needed to support increased sales and the impact of certain tax items in the quarter. Turning to Chart 7, let's review the adjusted EBITDA bridge for the fourth quarter.
Fourth quarter of 2021, adjusted EBITDA was $307 million, up $61 million from the same period in 2020. Price was a large contributor to the improved results. But pricing gains across the entire portfolio. However, the impact volume gains across most of our segments was more than offset by demand headwinds from automotive OEMs primarily related to the impact of semi-conductor shortages on auto builds. Our net price versus cost contribution continues to be positive despite inflationary environment we are in.
As I said in the last quarter, we continued be vigilant across our businesses to ensure that we stay ahead of inflation. Turning now to Chart 8, our cash position, liquidity, and balance sheet remains strong as they have throughout the year. Our cash balance at the end of the year was $1.45 billion, up from $1 billion in the prior quarter. In the fourth quarter, we generated $214 million of operating cash flow and CapEx was $83 million. We returned $134 million of cash to shareholders through dividends and share repurchases. We reduced our debt by $17 million and proceeds from the mining solution sale were also recognized in the fourth quarter. We ended the year with gross debt of $3.8 billion. Our net leverage ratio improved to 1.8 times on trailing 12-month basis, down from 2.3 times in the prior quarter.
Total liquidity stands at approximately $2.3 billion, including revolver availability of approximately $800 million. Turning to Chart 9, as we continue to strengthen our cash and ration, we also continue to execute on our disciplined approach to capital allocation. In 2021, we invested $277 million in CapEx to maintain our assets, meet our CRC commitments, and grow the business long-term. The timing of our capital expenditures in 2021 was impacted by labor and material issues, which shifted several projects from 2021 into 2022. From our credit profile perspective, we reduced debt by $204 million in 2021. And we also contributed $100 million earlier in the year into the escrow account as per the MOU agreement with DuPont and Corteva. This amount is reflected as restricted cash on our balance sheet.
Last but not least, we continue to return the majority of our free cash flow to our shareholders with $164 million returned via dividends and $173 million through share repurchases in 2021. Since then, we have retired more than 10% of our total shares outstanding, going from approximately $181 million shares to approximately $161 million shares at year-end 2021. Let's now turn to Chart 10, where I'll cover the results and outlook for our Titanium Technologies segment. Our Titanium Technologies segment continued to deliver in 2021, with strong performance over the course of the entire year, despite global logistics issues and feedstock disruptions. Tighter pigment demand was strong across all regions and all end markets, as the global economy recovered from the low levels we saw in 2020.
Our 10 year strategy continues to deliver with strong traction across all three sales channels. Customers continue to see the value of a long-term relationship with Chemours as a reliable, high-quality supply has enabled them to succeed despite other supply chain issues. As a result, our contracted customer base has never been stronger and we have welcomed many new customers in our flex portal who want to buy tightly of Anco Motors. Turning to the results, fourth quarter net sales rose 25% to $865 million versus the prior year quarter. Price rose 19%, while volume rose 6% on a year-over-year basis. Fourth-quarter adjusted EBITDA of $198 million improved 33% versus the prior year quarter. Segment margins were a healthy 23% despite ongoing older logistics constraints.
Sequential price of 5% more than offset increased costs in the quarter. For the full year 2021, net sales were $3.4 billion up 40% from $2.4 billion in 2020. Price rose 10% and volume was up 28% as demand return from pandemic-induced lows in 2020. Adjusted EBITDA rose 59% to $809 million from $510 million in 2020. Full year margins came in at 24%. We exited 2021 having greeted all of the share loss on installation of our TVA strategy and then some. Price stayed ahead of rising costs throughout the year despite inflationary environment with higher-cost required to support by production.
Looking ahead, we anticipate strong demand for [Indiscernible]] pigment to continue in all geographies and end markets. At the same time, order constraints are likely to continue into the first part of the year, but will moderate over time. As Mark said earlier, we have never felt better about the customer book we have built and look forward to continuing to serve them with the highest quality type of pigment available in the market today. Turning to Chart 11, thermal and specialized solutions delivered a strong fourth quarter and full-year 2021. Driven by improved demand despite headwinds from automotive OEMs related to semi-conductor shortages.
Our execution throughout the year was solid, and we continue to execute on pricing initiatives to stay ahead of rising raw material costs. The breadth of our portfolio across victory, aftermarket, and non-refrigerated applications enabled us to deliver solid financial performance despite the drag off, automotive OEM demand headwinds, and contractual price downs. Looking more closely at the results, fourth quarter net sales improved 8% from the prior year fourth quarter. Strong price contribution in the quarter of 19% more than offset the impact of 11% lower volumes. As a reminder, the fourth quarter of 2020 was an exceptional quarter from an auto OEM demand perspective. But bills have been down across 2021 due to semi-conductor shortages.
As a result of these headwinds, adjusted EBITDA declined 8% to $97 million in the quarter. For the full year, net sales rose 14% to $1.3 billion as a result of stronger volumes and price that rose 9% and 4%, respectively. Full-year adjusted EBITDA was $412 million, up 16% from $354 million in 2020. Adjusted EBITDA margins improved from 32% to 33%, demonstrating the earnings power of the segment. We delivered solid growth in both legacy refrigerants and low GWP Opteon refrigerants across most end markets. As we look ahead, we expect a continued market recovery in 2022 with recovery in automotive OEM build rates from the semiconductor-related shortages of 2021.
The U.S. Aim Act and additional F-Gas enforcement in Europe will drive continued conversion to Opteon, low global warming potential solutions. At the same time, we continue to enter new markets with innovative products, including Opteon 1150, our newest, low GWP foam blow agents. Chemours remains well-positioned to be a sustainable [Indiscernible]] of management provider of choice for our customers. Let's now turn to Chart 12 for our Advanced Performance Materials segment. The APM segment has delivered outstanding results throughout 2021 and exceeded our own expectations for profitability throughout the year. As the business has continued its turnaround, the power of our chemistry continues to shine. From farmers to membranes, the portfolio contained class-leading products which are key to unlocking the future potential of high-growth end markets in clean energy and advanced electronics. Sales at an all-time record of $346 million in the fourth quarter, up 24% from $279 million in the prior year fourth quarter.
Strong demand drove 10% price and 15% volume gains on a year-over-year basis. It's strong demand underpinning growth across the breadth of the portfolio. Adjusted EBITDA rose 160% to $65 million as price actions and productivity, more than offset sharply higher energy and logistics costs in the quarter. For the full year 2021, we delivered record net sales and adjusted EBITDA of $1.4261 billion respectively.
The top-line grew 27% from 2020 levels, with 20% volume growth reflecting strong demand across all product lines. Price growth, and currency contributed 4% and 3%, respectively to the top-line growth. We continue to experience a favorable price cost dynamic across a diverse product portfolio per segment. And as a result, margins expanded to 19% in 2021 from 11% in 2020. This achievement was exceptional given the logistics and weather-related challenges we experienced during the year. Looking ahead, we believe that strong underlying demand will continue into 2022. We anticipate headwinds from raw material costs, energy, and logistics of moderate over the course of the year.
In total, we continue to target top-line growth in excess of GDP. We are also targeting adjusted EBITDA margins in the low 20% with operating discipline and efficient plant operations helping to offset rising input costs. We see significant market momentum building in clean energy and advanced electronics, where our technology is uniquely suited to drive higher levels of performance. Whether it's a [Indiscernible]] members in hydrogen, our teflon PFA in semiconductor fabs are [Indiscernible]] on to last tumors in electric vehicles. ATM is playing a leading role in enabling the technologies that will help shape the future. Turning to Chart 13, we continue to focus the overall portfolio of Chemours and completed the sale of a mining solutions business in the fourth quarter.
Compatibility of results in the fourth quarter and full year for Chemical Solutions segment was impacted by these portfolio actions. That said the underlying business performance in PC&I and mining solutions was solid throughout the year. Fourth quarter net sales were $69 million as the impact of price and volume gains of 8% and 14% respectively was more than offset by portfolio changes. Adjusted EBITDA was $8 million in the fourth quarter of 2021, again, reflecting the impact of portfolio changes in the quarter. For the full year, net sales were $336 million while the full-year adjusted EBITDA was $51 million.
Strong demand in pricing gains across most end markets and key product lines contributed to the solid results. Looking ahead, the segment is now focused on a world-class glycolic acid franchise. We anticipate solid growth in 2022 across both technical and high-purity grades of product, along with continued expansion into new markets such as Clean & Disinfect and Electronics. With that, I will turn things back over to our CEO, Mark Newman to cover our 2022 guidance. Mark.
Thanks, Sameer. I will continue my remarks on Chart 14. Our business results have continued to improve steadily, and are no well above pre -pandemic levels reported in 2019. A result of the hard work of our employees and execution of our focused strategies. As we look ahead to 2022, we believe our results will continue to improve with another year of solid earnings and cash flow growth. Our full-year adjusted EBITDA is projected to be between $1.3 and $1.425 billion, up 8% at the midpoint after accounting for the divestiture of our mining solutions business at the end of last year. We project adjusted EPS of between $4.7 and $4.70.
Finally, we forecast free cash flow of greater than $500 million in 2022, inclusive of CapEx of approximately $400 million. Taken together, these results reflect the higher quality business we're driving across Chemours and our ability to improve earnings through the cycle. From a capital allocation perspective, we remain committed to returning greater than 50% of that free cash flow to our shareholders in the form of dividends and share repurchases. To that end, we expect to complete the remaining portion of our $1 billion share repurchase authorization by mid-2022. With the momentum we have built in 2021, we believe 2022 will be in another excellent year for Chemours and for all our stakeholders. I would like to close with some thoughts on the next chapter of Chemours.
At spin, we set out to create a new kind of chemistry company. One which would have the courage to make difficult decisions and lead the industry forward. The foundation which has been laid is strong. As we look to the future. The next chapter of Chemours, Chemours 2.0, as we call it, will refocus our efforts to create a better world to the power of our chemistry. This vision will be underpinned by four key elements: agile, innovation and sustainable solutions, environmental leadership, community impact, and making Chemours the greatest place to work for every employee.
To that end, I have challenged every Chemours employee to ensure their work helps to contribute to these goals. I truly believe the spirit of this vision, owned collectively buyer 6400 employees, can take the company to new heights, and it will reward our customers, our planet, our team, and of course, our shareholders. I'm excited to be leading Chemours on this leg of the journey and look forward to engaging with all of you in the coming year. With that Operator, please open the line for Q&A.
[Operator Instructions] We'll pause for just a moment to compile the Q&A roster. And your first question comes from the line of John Silverstein from Wolfe Research. Your line is open.
Okay, good morning, guys. For 2022, you're still factoring and continued or constraints and supply chain issues and raw material inflation. Are you factoring in to get worse relative to the fourth quarter versus or improvements throughout the course of the year? And then if there continues to be or constraints, what are the supply alternatives for that?
Hey, good morning, John. Mark here. Our guide really assumes that we continue to build momentum in all three of our industry-leading businesses. And on TiO2 in particular, we were down sequentially in the quarter, in line with expectations from a volume perspective on very strong demand. But as we had indicated in our Q3 call, we were ore constraint and we expect that ore constraint to relieve itself in the first half of the year. So we start the year with ore constraint.
Our expectation is volumes will be relatively flat from Q4 to Q1, but will then mirror more over the seasonal patterns beyond that as the ore situation resolves itself. So great -- good quarter on a great year. But I just wanted to share with you that we see real good momentum in all of our businesses, especially from a demand and the pricing perspective, which we expect to continue.
Thanks for that. And then, just on pricing of the TBS model, you pushed through 5% increase this quarter on top of 6% increase in the third quarter, with inflation indicators considering to gross higher and higher, is the expectation for you guys to keep being able to push through higher prices in 2022? Thanks.
So the short answer is yes and as you'll see in our EBITDA bridge, we are continuing to be able to take price across our entire businesses in excess of costs. Clearly, you're going to have some lumpiness as you move through time. So it's not always perfect timing in terms of how those two move together. But recall that we have three go-to-market approaches on the TBS which provide us real price latitude. Maybe I'll ask Sameer to comment on that because that's something that we watch very carefully.
Thanks, Mark. John, look, you touched on the AVA contract for the same time in flex and distribution as Mark talked about there's an opportunity to push prices even faster than the AVA contracts, right? So all-in-all, we feel pretty good about where the supply demand is and what our opportunity is to pass through prices.
And Josh, bottom line, I would say our expectation is to have our TiO2 business. For the full year we were at a 24% EBITDA margin. Our expectation on this business is to be in the mid-20s going forward. Clearly, you had a cording which we had lower volumes related to ore. And as that relieves itself, our expectation is to both price as well as volume. We would return this business to mid-twenties going forward.
Your next question comes from the line of John McNulty from BMO. Your line is open.
Thanks very much for taking my questions. So a question on the TSS business. Just in terms of how you're thinking about how 2022 plays out. I know we had some of the issues around autos being a little bit weaker in the back half of the year. I assume that's there's an assumption in your guide for a recovery there. You also had some really strong pricing as well so I guess, can you speak to how you're thinking about how that business progresses in terms of earnings trajectory through 2022?
Yeah. John, thanks for the question. TSS had a good year despite the auto OEM headwinds and of course, we had the winter storm Uri that impacted our Corpus Christi plant early in the year. So when you look at the year of being up 14%, but greater than 30% margins with all those headwinds, really great job by the team. When we look at IHS forecasts for auto builds, we expect that to be in line with those projections. Clearly, we're focused on both the OEM and aftermarket growth in Opteon. And so we feel quite encouraged by that. And our guide reflects the continuing improvement of the auto as we go through the year.
On the pricing side, we're seeing a better market in the stationary, mainly here in North America, but also in Europe. And as we get through this next COVID wave, our expectation is we will see a lot more folks returning to offices, business travel, picking up. We will see a lot more normal recovery in the commercial aspects of the refrigerant demand across the spectrum. So quite encouraged by early indications in the year. But clearly, we have a cautious note in our guidance until the auto OEM situation clears itself.
Got it. Got it. That's helpful. And then maybe just as a follow-up, a kind of a broader question. So when I look at the guidance that you provided, it's a pretty wide range, admittedly. And look at the decrease a year to start. So maybe that's part of the rationale. But when I look at the low end of the range, I mean it's basically pointing to when you adjust for the [Indiscernible]] sale, about 1.5% to 2% EBITDA growth, which given the outlook that you laid out for TiO2, the outlooks that you laid out for TSS. And what I would think it's going to be continued decent demand growth in the APM segments.
Candidly, I can't figure out what could get you to that low end of the range. So can you help us to at least frame the risks or the potential that, or the things that could go wrong, maybe put you toward that low end of the range, or is it just, hey, look, it's early and we don't want to get -- we don't want to set the bar too high type of thing? Like --
John, I'd say it's early, and we're starting the year, obviously with a number of uncertainties. We did mention being or constrained in TiO2. We're seeing -- we're not through the Semicon issue with auto. There has been some auto disruptions even in the quarter an unrelated to Semicon. And so I think it's just starting the year with a lot of uncertainty and having some caution in our guidance. But I would not factor anything more into that than this being thoughtful early on in the year.
Got it. Thanks very much for the color.
Thank you.
Your next question comes from the line of Bob Koort from Goldman Sachs. Your line is open.
This is Emily CAC on for Bob. So looking again at the 2022 outlook, it reflects a continued economic recovery and you guys mentioned the expected supply chain normalization in early 2022. So just across the businesses, what trends have you seen that give you confidence in that normalization?
Yes. So Emily, great question. I would start by saying that demand remains strong in all key markets and all key product lines. And in fact in many cases, we are -- we remain sold out and pricing power is in our favor. Obviously, we are working carefully with our customers to make sure we're not doing anything that's disruptive. But as I look at it, clearly, demand is strong at the outset. But we're somewhat constrained, especially in TiO2 as we start the year. So I think our guidance really reflects growth -- top-line growth in all of our businesses this year.
Clearly, if I go through the businesses, we're -- outside of TiO2, we will be looking at the impact, starting the impact of the AIM Act in our TSS business, where we're going to start to see more traction on some of our blends businesses in refrigerants. Our expectation around our APM business is that the GDP plus growth from this point on because of all the secular trends related to both Semicon and EVs that are driving our portfolio.
Okay, great. And then just one more. Can you provide more color on the new strategic partnerships you mentioned in the TNSS business?
Yeah. Let me just jump in. It's -- these are the strategic partnerships that we have with the automo -- sorry, with the HVAT OEMs. Some of these are public and some are, of course, not in the public domain but across the broad spectrum of OEM suppliers. We have been working -- and as they transition to a new equipment. As the Aim regulation comes in, yes, it will be initially the blend portfolio, but all the OEMs are working through their models and upgrading how they will work with the new refrigerant. So there's a great exciting opportunities to be working with our key customers, and to help them transition into the new product lines.
Thank you.
Your next question comes from the line of Arun Viswanathan from RBC Capital Markets. Your line is open.
Great. Thanks for taking my questions. I guess, first off, just real quickly on the cash usage. Maybe you can just go through and order your priority uses of cash. It looks like you do have quite a bit of cash on the balance sheet there, and about close to $1.5 billion, $1.45 billion. But it sounds like your buyback plans are for about $2.15 billion in the first half. How do you plan to spend the remainder of the cash there? Thanks.
Arun, great question. I'll start and ask Sameer to follow on as well. Clearly, when you look at our free cash flow generation in 2021 and the guide that we've given for this year, this will be the third year of free cash flow greater than half a billion. What we want investors to understand is, this is a franchise which has improving earnings quality across all three businesses and significant cash conversion. This is a management team with support from our Board that believes in returning the majority of free cash flow to our investors. And in 2021 coming out of COVID-19, we thought a more balanced approach with that in mind made sense. And so you see, we made really good gains in terms of improving the strength of our balance sheet and our leverage ratios, as well as returning the majority of free cash flow.
We actually stepped up the cash flow to shareholders, more so in the second half of last year, as we got more confident on the full-year outlook. And we're coming into the new year and stepping that up again. So we have $250 million remaining on our current share buyback authorization. And our commitment is to have that completed in the first half of this year consistent with the cash generation of the business going forward. Maybe Sameer, if you have any other thoughts?
Thanks, Mark. Arun, I will just go back to, Harvey talked about the cash used in the past. But we as a manufacturer of our product, in terms of investing in our cash is to make sure we have safe and reliable operations. As you know, we have our responsibility commitments that we have to ensure we can cut down on the emissions, and our -- there are some pretty attractive growth opportunities as well, as Mark talked about. But AIM Act and all the stuff that's happening around semiconductor on-shoring, it's a great exciting opportunities for us on both of the APM, TSS and TT franchises. We first -- our first priority is to make sure we do the right CapEx, and that's why you've seen in the guide roughly $400 million of CapEx.
And I would -- the way I would look at CapEx, as I said in my remarks is number of projects move from '21 into 2022. So combine that '21 and '22 years, $50 million of CapEx. And also that as Mark said, we will do look over debt reduction. We are committed to our $3.5 billion gross debt target. We made pretty significant improvement in that. We'll continue to our march forward on that. And then last is commitments stays that we will return majority of free cash flow to shareholders. So if you look at our comments around that we expect to finish the remaining commitment on the buyback program in the first half that's roughly $250 million of cash coming back to the shareholders. We have repurchases just in the first half of the year. So that's how you should think about our cash usage investment, credit profile enhancement, and majority cash coming back to shareholders.
Okay, thanks for that. And just as a follow-up. I wanted to understand the high-end of the guidance. I know there's about a $60 million difference between the midpoint versus the high-end sell. Would you characterize that as mostly possible that $60 million and APM and TSS, if there's quicker resolution on chip shortage issues or supply chain. Is that the right way to think about it? Thanks.
Yeah, Arun. There are lots of puts and takes, but I would say it's pretty balanced. Look, when there are growth opportunities across all three businesses, right? Or situation are resolved I think on the TiO2 side. As Mark said earlier, the demand remains really strong. So there's an opportunity from there from a midpoint to the high-end and the TSS you hit the nail on the head. If the auto OEM market recovers, I think that provide just some pretty interesting exciting opportunities. F-Gas regulation, Mark mentioned about AIM Act for the same time as the enforcement increases in Europe on the F-Gas that provides us an opportunity as well. And similarly, on the APM side, I mean, as we talked about the margin improvement as the efficiency of the operation improves, getting into the margins in the low 20% that provides us a great opportunity as well. So it's an opportunity rich environment and on across all our three businesses. So on the high end, I would keep it pretty balanced.
Arun as I said, we really love the momentum we have in all of our businesses. Obviously, we're being very thoughtful on our guide early in the year. But when I look at TiO2, we have the best book of business that we've ever had. And we can grow with our customers. We are working to unlock the bottleneck capacity to achieve that growth. When I look at TSS, we have the recovery of auto, plus the growing impact of Aim over time, as well as just more commercial refrigeration as things go back to normal post - COVID.
And then in APM, we're working on so many exciting opportunities from Semicon to hydrogen to EVs to advanced electronics where our fluoropolymers really are the only the only answer to sort of solving the world's most difficult issues. So I'm very excited about the potential of these three businesses, and the focus we have of our leadership team and our employees, to keep driving forward.
Your next question comes from the line of Duffy Fischer from Barclays. Your line is open.
Good morning. First question is just around your free cash flow. Last year, you guys did about 41% conversion from EBITDA to free cash flow, it's the midpoint this year that would give you $564 million of free cash flow, which is a big distance. It's within the guidance, but it's much higher than the 500. Is that conversion ratio still good in your mind or are you likely to convert less EBITDA to free cash flow this year than last year?
No. Duffy, this is Sameer. Let me just take that one. As you look at the 2022 verses 2021, I think that one of the biggest drivers was just CapEx as we move from this year to next. As I said just to Arun, CapEx is going up. It's just a transition given how some of the projects got delayed. And also, I think from the working capital perspective, this is a year in which we will be more seasonal in terms of the working capital consumption and release of the working capital. So that's going to have a little bit of impact as well. 2019, 2022 inventories have been pretty light across the chain and that applies to us as well. So as we move into 2022, you're going to see some of the working capital stuff as well. So all in all, I would say combination of the two years given the CapEx movement makes more sense the way you look at it.
Fair enough. And then, a couple of quick ones just on TiO2. One, as you exited last year, what percent of your TiO2 was on the AVA contracts? And then, two, if you look at the tonnes you produced last year, where is that relative to your capacity so we can build in if we think things are going to grow, how many more tons we're going to be able to add over the next couple of years to your revenue mine?
Yeah. Duffy, we've guided to about 70% of our book of business is contracted, and the rest is either our distributor business or our flex portal. And we also laid around that from quarter-to-quarter, but that's a pretty good guide. What I'd tell you is in 2021, our mix of contracted business really improved. We used the market tightness as a way to enhance both product and customer mix throughout the year. To where we can now say this is -- we're supplying the best set of strategic customers with the best contracts that we've had in our history. So I'm really encouraged by that. Clearly the impact of, or as it relates to capacity had an impact on our Q4 volumes and we're starting the year that way so we would expect our volumes to be relatively flat from Q4 to Q1. But beyond that, we would expect to be able to show volume growth as well given our capacity.
Terrific. Thank you, guys.
Thanks, Duffy.
Your next question comes from the line of Vincent Andrews from Morgan Stanley. Your line is open.
Thank you. And good morning, everyone. Could you just give us a sense of the visibility you have on your supply improving for -- after the first half? I just ask regarding situation has gotten more challenging over the last three months. I Just like to get a better sense of how much comfort you have in that view on work.
Yeah. I would say, the main thing that we were watching currently is ore supply to TiO2. Vincent, that related to some enforcement sure activity in Q3 of last year, which we see improving as we move forward in time. Clearly, even though things at the mine face are improved, you still have the impact of a pretty congested logistics. So that's really playing into our near-term performance. But again, our RBO is -- we see that resolving itself here in the first half, and we expect to have more to say at the end of Q1.
And just as a follow-up, if I look at your historical balance sheet and the cash balances at the end of the year, the lowest number I see in 2015 is $366 million. Is that for walking around assumption, is that the amount that you could comfortably finish the year with on an ongoing basis or would you need more than that?
Yeah. Vincent, this is Sameer. Look, it really depends on the needs of the businesses and what kind of investments you're looking at the U.S. versus non-U.S. cash. What I would say is the balance sheet cash you should really look in the context of where we're spending. Our view is we continue to make investments in our businesses both on the run and maintain reliability perspective. And make -- continue to make progress on our CSD commitments, get a balance sheet debt back to $3.5 billion range. So we are committed to that and then go back to returning majority of free cash to the shareholders. That's how I would look at it. The exact balance sheet cash, as you know, can move around based on where the needs are and also really importantly how we generate the cash into U.S. versus non-U.S. and making sure we have enough U.S. cash.
Thanks very much.
Thank you.
Your next question comes from the line of Josh Spector from UBS. Your line is open.
Hey guys, thanks for taking my question. Just a couple of one's take on Oregon. Just as or limits supply I guess, is it fair for me think about most of your North America sales to the AVA 's already. So they get perhaps first dibs at North America supply, and does that mean that Europe gets a bit shorted in the near-term the next couple of quarters. And just on your 2Q seasonal ramp comments, I assume for you to meet that you need the ore for 2Q already on the water and ships now, is that in place to get it 2Q seasonal ramp?
I said earlier, the issue at the mine has largely been resolved and we're seeing improvements there and shipments are on the water, so yes. The last question [Indiscernible]], the short answer is yes. Obviously, it's something we keep monitoring. Clearly, we are very focused on meeting our contracted book of business and their customer needs first. And when I look at our growth in 2021, we grew in all markets. So there's no North America versus Europe versus AP trade-off here. The trade-off is, hey, you make sure you deliver first and protect your contracted book of business. And that's candidly part of the value prop that so many customers have flocked to, or being contracted with Chemours. In the short-term, it will put a little bit more volume on some percentage on our ABA book. But again, this is just a matter of a couple of quarters here where we're somewhat ore constraint.
And maybe another way to ask that is, is your flex quartile distribution significantly different than your average? I would think maybe ATP, perhaps as more of the spot market activity, is that a fair way to think about it?
Our Flex portal is available to our global customers, so customers around the world in different markets. The availability on Flex is somewhat reduced when you're constrained. And then that usually results in prices on Flex, which reflect the spot markets being significantly higher. So that's -- We always want to have volume available for Flex and distribution because of the opportunity brings in a tight market like we have. And that's why we've made this rule of thumb that we would constrain our contracted book of business to about 70% of our volumes.
Okay. Thank you.
You're welcome.
Your next question comes from the line of Matthew DeYoe from Bank of America. Your line is open.
Good morning. Thanks. A few quick ones on the TSS volumes. So if the business was down 11%, does that mean Opteon was down closer to 18 to 20? And why did it take until 4Q to see that headwind given what we've just saw transpiring even at 3Q? I know you mentioned comps from last year. Is that the case? And what do we see this type of -- should we see this kind of volume print consistently until we get to the back half of next year when things ease up a little bit?
Now, as I'll start and maybe ask Sameer to comment a little bit further. Recall Q4 of last year was a very robust recovery for auto. It's just a tough year-over-year comp on auto volumes, vis a vis the Semicon constrained build and Omicron constrained build in Q4. The way you should read that is just a year-over-year comp. Our expectation, and I think if you look at IHS outlook, they're projecting order volumes this year to be up around 10%. And so we are using IHS as the guide. Clearly, we're focused on both OEM and aftermarket opportunities as the Opteon car park continues to build.
Okay. And then a quick one on PFOA. So DuPont made some comments about making progress on settlement work they really didn't go in to a lot of detail on the call and maybe it's on purpose but there's kind of this outstanding South Carolina MDL and perhaps other cases, just kind of wondering through what the cadence of any kind of announcements we might get through the year or what you're looking at and how you frame out liabilities versus perhaps risk to setting precedent.
Josh, I wouldn't speculate on cadence, but I'd make two comments here. First is DuPont, Corteva, and Chemours continue to work well together under the MOU framework and you saw that this year with the Delaware settlement that we announced last year. Secondly, as a leadership team, we're always open to potential for settlements that reduced the risk to the company, but are done in in way that we believe create value to our shareholders. And so we will continue to have that mindset. I'm very encouraged by the fact that, in my discussions with DuPont and Corteva, we have a shared view of using the MOU to work through issues that relate to our legacy paths. So stay tuned, but nothing more to say at this time.
Understood. Thanks.
Your next question comes from the line of Eric Petrie from Citi. Your line is open.
Hi. Good morning, Mark and Sameer.
Hi, Eric.
Hi, Eric.
I saw your second patent infringement case in Japan and it's a good example of enforcement. But I was wondering, could you give an overview of your patent estate? And when could we expect the competitor to produce in HFO for the auto air conditioning market?
Hey, we continue to view our passengers state as going well towards the end of this current decade. And we will vigorously depend -- defend our IP estate globally. And so I just say we continue to innovate around our Opteon franchise, bring new IP to market that makes our product better for our customers. And we would expect to continue to have significant IP defenses through the -- through latter half of this decade.
Okay. And then secondly on TiO2, given the shipping and logistics and strengths, did you have to reroute any of your TiO2 volumes? I know Altamira is a big exporter of TiO2, so any changes in trade routes?
Hey Eric, this is Sameer. Nothing of significance. Look, there's always supply chain teams making some adjustments here and there based on the port availability and the vendors to be used, but nothing material.
Eric, I'll just say this year our operations teams worked hand-in-glove with procurement and logistics and our customer service organization to ensure minimal disruption to our customers. And we -- you don't build up book of business like we have by not really taking seriously your value prop to your customers. So I really -- it was a year where we had collaboration across all aspects of the organization but a big shout out to our ops teams who despite three waves of COVID run our plants really well and worked with our logistics team to make sure our customers had minimal disruptions.
Thank you.
Your next question comes from the line of Hassan Ahmed from Alembic Global. Your line is open.
Good morning, Mark.
Hi, Hassan.
How are you doing?
Great.
Question around Titanium Technologies. Look, sequentially, your volumes were down 10%, and I obviously understand the seasonality of things, I understand supply chain constraints, considerations, and the like but one of your larger competitors back in November had guided to volume decline sequentially in the mid-single-digits. So I'm just trying to understand, did you guys lose some market share in Q4 or was that just the way the market was? And part and parcel with that, on a go-forward basis in 2022 now that you guys stated that you've regained your lost market share, how should we think about your volumes in TiO2 year-on-year? Will you grow with the market or will you continue to try to regain market share as you consider the bottlenecks and the like?
Yeah, Hassan, it's a great question. And clearly, among competitors, you will have variation quarter-to-quarter. But when you look at our overall volumes for the year, TiO2 revenue up 40%. It's hard to argue with the result that we had in the year. Sameer said in his remarks, we regained the market share we lost with TBS and then some. So our focus here is to really maintain our market share, maintain slash grow our market share. And but by doing that, by growing with our customers first. We have really, really good strategic book of business and our focus now is how do we grow as our key strategic customers grow.
As it relates to sort of a volume outlook for the year, clearly, we are starting the year or constrained. And as I said earlier, we expect that to alleviate itself as we move through the first half. And our expectation is based on the strength of the market we're seeing and how light inventories are throughout the whole system, that we should have another great year in terms of revenue growth in this business.
Understood. And as a follow-up, just sticking to TiO2 again. As you sit there and look at where the cost curves are today with -- you rightly pointed out or constraints obviously, or pricing -- the prices going up. But also the chlorine side of things, all in out there, shuttering as much as 15% of their capacity. Could 2022 be a year where you see major differences between the integrated TiO2 producers versus the non-integrated ones? And again, I'm thinking about the flexibility that you guys have in toggling between a whole range of force. So could this be a year where the non-integrated feast or famine relative to whether you're integrated or not?
So listen, we like our book of business. We like our supply on all of our route [Indiscernible]]. We continue to work across both chlorine and ore to be well supplied through time. So I just say -- And then we like our cost curve, where we are on the cost curve. And as we debottleneck capacity, we're seeing opportunities to do that at some of our lower-cost plans as well. So overall, Hassan, I remain very encouraged about where we are in our TiO2 journey. Clearly, we're starting the year slightly more constrained, and that's something we'll work our way through.
Very helpful.
The only other thing, Hassan, I would add is, look, if you look at the quality of our operations and technology in TiO2 I won't exchange that for anything else. At the end of the day, what matters is return on capital and with our technology we believe we have very attractive return on capital in the broader scheme of things. So we take our pride in that.
Perfect. Thank you so much.
Thanks.
And there are no further questions at this time. Mr. Mark Newman, I turn the call back over to you for some closing remarks.
Yes. Thank you. And listen, we are very excited about the momentum we have in all of our businesses. We're starting the year with very strong customer demand. And our focus this year will be continued to grow earnings and just throw our significant free cash flow as we grow revenue and earnings going forward. Thank you for your continued interest and we look forward to speaking to many of you today.
This concludes today's conference call. Thank you for your participation. You may now disconnect.